Alcohol use disorder (AUD) is the most prevalent substance use disorder and causes a
significant global burden. Relapse rates remain incredibly high after decades of attempting …

Excessive alcohol consumption is involved in 1/10 of deaths of US working-age adults and
costs the country around $250,000,000 yearly. While Alcohol Use Disorder (AUD) pathology …

Clinical and preclinical studies have shown that ketamine, an NMDA receptor antagonist,
has promising therapeutic value for the treatment of alcohol use disorder (AUD). However …

Introduction Alcohol use disorder (AUD) is the most prevalent substance use disorder (SUD)
globally. In 2019, AUD affected 14.5 million Americans and contributed to 95,000 deaths …

Alcohol use disorder (AUD) is a chronic, recurrent condition that demonstrates significant
heterogeneity in treatment response to first-line agents. Ketamine may have a therapeutic …

Background Worldwide, alcohol abuse is a burgeoning problem. Abstinence is key to allow
recovery of physical and mental health as well as quality of life, but treatment for alcohol …

Background: Despite advances in behavioral and pharmacotherapy interventions,
substance use disorders (SUDs) are frequently refractory to treatment. Glutamatergic …

Ketamine is a dissociative anaesthetic drug which acts on the central nervous system chiefly
through antagonism of the n-methyl-d-aspartate (NMDA) receptor. Recently, ketamine has …

Background A number of studies have demonstrated the significant and rapid
antidepressant effects of ketamine, which is also known as a neurotoxic and illicit drug …

Background Alcohol use disorder is highly prevalent and has important economical,
societal, psychiatric, and medical consequences. All currently approved therapeutic …